David N. Matlock

David N. Matlock

Auto-generated profile, based on publicly available information

David N. Matlock

University of Arkansas for Medical Sciences, Little Rock, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
DMDavid N. Matlock
David N. Matlock
SBShasha Bai
Shasha Bai
MWMichael D. Weisner
Michael D. Weisner
NCNorman Comtois
Norman Comtois
JBJennifer Beck
Jennifer Beck
SCSherry E. Courtney
Sherry E. Courtney

1 March 2022 in The Journal of Pediatrics
Verified
Journal Article
Closed access
RMRobin McKinney
Robin McKinney
NNNatalie Napolitano
Natalie Napolitano
JLJonathan J. Levin
Jonathan J. Levin
MKMatthew J. Kielt
Matthew J. Kielt
SASteven H. Abman
Steven H. Abman
MKMartin Keszler
Martin Keszler

20 March 2024 in Trials
Verified
Journal Article
Open access
PDF file
DMDavid N. Matlock
David N. Matlock
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
SCSherry E. Courtney
Sherry E. Courtney
HKHaresh Kirpalani
Haresh Kirpalani
KFKimberly Firestone
Kimberly Firestone
EFElizabeth E. Foglia
Elizabeth E. Foglia
Background: Invasive mechanical ventilation contributes to bronchopulmonary dysplasia (BPD), the most common complication of prematurity and the leading respiratory cause of childhood morbidity. Non-invasive ventilation (NIV) may limit invasive ventilation exposure and can be either synchronized or non-synchronized (NS). Pooled data suggest synchronized forms may be superior. Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) delivers NIV synchronized to the neural signal for breathing, which is detected with a specialized catheter. The DIVA (Diaphragmatic Initiated Ventilatory Assist) trial aims to determine in infants born 240/7–276/7 weeks’ gestation undergoing extubation whether NIV-NAVA compared to non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV) reduces the incidence of extubation failure within 5 days of extubation. Methods: This is a prospective, unblinded, pragmatic, multicenter phase III randomized clinical trial. Inclusion criteria are preterm infants 24–276/7 weeks gestational age who were intubated within the first 7 days of life for at least 12 h and are undergoing extubation in the first 28 postnatal days. All sites will enter an initial run-in phase, where all infants are allocated to NIV-NAVA, and an independent technical committee assesses site performance. Subsequently, all enrolled infants are randomized to NIV-NAVA or NS-NIPPV at extubation. The primary outcome is extubation failure within 5 days of extubation, defined as any of the following: (1) rise in FiO2 at least 20% from pre-extubation for > 2 h, (2) pH ≤ 7.20 or pCO2 ≥ 70 mmHg; (3) > 1 apnea requiring positive pressure ventilation (PPV) or ≥ 6 apneas requiring stimulation within 6 h; (4) emergent intubation for cardiovascular instability or surgery. Our sample size of 478 provides 90% power to detect a 15% absolute reduction in the primary outcome. Enrolled infants will be followed for safety and secondary outcomes through 36 weeks’ postmenstrual age, discharge, death, or transfer. Discussion: The DIVA trial is the first large multicenter trial designed to assess the impact of NIV-NAVA on relevant clinical outcomes for preterm infants. The DIVA trial design incorporates input from clinical NAVA experts and includes innovative features, such as a run-in phase, to ensure consistent technical performance across sites. Trial registration: www.ClinicalTrials.gov, trial identifier NCT05446272, registered July 6, 2022.

18 February 2020 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
DMDavid N Matlock
David N Matlock
SBShasha Bai
Shasha Bai
MWMichael D Weisner
Michael D Weisner
NCNorman Comtois
Norman Comtois
JBJennifer Beck
Jennifer Beck
SCSherry E Courtney
Sherry E Courtney
BACKGROUND: We tested whether work of breathing in premature newborns estimated by phase angle (θ) by using respiratory inductance plethysmography is decreased during neurally-adjusted ventilatory assist (NAVA) noninvasive ventilation (NIV) versus NIV alone. METHODS: NAVA NIV and NIV were applied in random order while using respiratory inductance plethysmography to measure the phase angle. RESULTS: Patient-ventilator asynchrony was decreased during NAVA NIV; however, the phase angle was not different between the modes. A large number of repeated assists with switches to backup were found when using NAVA NIV. Results of the analysis indicated these were due to the apnea alarm limit set during NAVA NIV. CONCLUSIONS: The improvement in patient-ventilator synchrony supports the hypothesis that work of breathing may be decreased with NAVA NIV; however, we were unable to demonstrate this with our study design. Short apnea time settings with NAVA NIV led to a large number of switches to backup and repeated assists during the same neural effort. (ClinicalTrials.gov registration NCT02788110.)

21 December 2023 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
ALAshley L. Lynch
Ashley L. Lynch
DMDavid N. Matlock
David N. Matlock
Chary AkmyradovChary Akmyradov
Chary Akmyradov
MWMichael D. Weisner
Michael D. Weisner
JBJennifer C. Beck
Jennifer C. Beck
SCSherry E. Courtney
Sherry E. Courtney

2 February 2021 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
DMDavid N Matlock
David N Matlock
SPSarah M Perez
Sarah M Perez
HBHeather A Borchert
Heather A Borchert
BPBetty L Proffitt
Betty L Proffitt
SPSara E Peeples
Sara E Peeples
ARAshley S Ross
Ashley S Ross
BACKGROUND: As part of efforts to decrease length of hospital stay, a protocol for weaning noninvasive respiratory support was implemented using quality improvement methodology. The objective of this study was to determine whether protocol implementation decreased the time to wean to no respiratory support by 24 h (30% reduction) over 3 months in preterm infants 30–34 weeks gestational age. METHODS: A quality improvement project was conducted with the following outcome measures: primary outcome measured was hours to wean; secondary outcomes included duration of respiratory support, length of stay, and postmenstrual age at feeding milestones; and balance measures were duration of oxygen exposure and growth velocity. RESULTS: Data from 89 subjects were included. Following implementation, decreases were seen in time to wean (40% reduction, P < .001), length of stay (25% reduction, P = .02), and growth velocity (21% reduction, P = .02). CONCLUSIONS: Implementing a weaning protocol decreases duration of support and length of stay in infants 30–34 weeks gestational age. Weaning respiratory support more quickly may decrease growth velocity.